The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

The insurers are looking to disrupt Big Pharma's model of distributing drugs. One of them's even offering to give them to ...

AbbVie ABBV announced that it has submitted a biologics license application (BLA) to the FDA seeking accelerated approval for ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in diagnostics and treatment, such as molecular ...